Literature DB >> 6882623

Pharmacokinetics of cyclophosphamide in Kenyan Africans.

F Juma, T Ogada.   

Abstract

The pharmacokinetics of cyclophosphamide was studied in 10 Kenyan Africans with Hodgkins lymphoma. The mean +/- s.d. elimination half-life (t1/2) was 7.5 +/- 1.38 h. The mean +/- s.d. volume of the central compartment (V1) was 0.35 +/- 0.12 l/kg and the apparent volume of distribution (V) was 0.64 +/- 0.06 l/kg. The microconstants k21, k12 and k10 were 1.81 +/- 0.84 h-1, 1.90 +/- 1.080 h-1 and 2.05 +/- 0.86 h-1 respectively (mean +/- s.d.).

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6882623      PMCID： PMC1427949          DOI： 10.1111/j.1365-2125.1983.tb02144.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Authors:  H T Mouridsen; O Faber; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-08

2.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

3.  Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.

Authors:  I Jardine; C Fenselau; M Appler; M N Kan; R B Brundrett; M Colvin
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

4.  Some aspects of the gas--liquid chromatographic analysis of cyclophosphamide in plasma.

Authors:  N van den Bosch; D de Vos
Journal:  J Chromatogr       Date:  1980-07-11

5.  The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

6.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

7.  Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.

Authors:  M Jarman; R A Milsted; J F Smyth; R W Kinas; K Pankiewicz; W J Stec
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

8.  Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

Authors:  F D Juma; H J Rogers; J R Trounce; I D Bradbrook
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
  9 in total
  4 in total

1.  Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma.

Authors:  F D Juma; D K Koech; E G Kasili; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

2.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.